Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Peripheral Blood Stem Cells

Transplantation of highly purified HLA-identical sibling donor peripheral blood CD34+ cells without prophylactic post-transplant immunosuppression in adult patients with first chronic phase chronic myeloid leukemia: results of a phase II study

Bone Marrow Transplantation volume 26, pages 823–829 (2000)Cite this article

Abstract

The feasibility of transplantation using highly purified G-CSF-mobilized peripheral blood CD34+ cells from HLA-identical sibling donors without prophylactic post-transplant immunosuppression was prospectively studied in 10 adult first chronic phase chronic myeloid leukemia (CML) patients with special reference to graft engineering performance and follow-up studies of minimal residual disease and immune reconstitution. CD34+ cells were enriched by clinical-scale magnetic-activated cell separation (MACS) using iron-dextran beads bound to monoclonal anti-CD34 antibody. Grafts contained a median of 9.7 (range 1.7–16.6) × 106 CD34+ cells per kilogram of recipient body weight with a purity between 94.5% and 98.3% (median 97.2%). The median number of transfused CD3+ T lymphocytes was 1.0 (range 0.5–8.5) × 104/kg, corresponding to a log10 t lymphocyte depletion between 3.8 and 5.0 (median 4.6). all patients engrafted rapidly with a median duration to neutrophil counts >500/μl of 8 (range 8–19) days and to self-sustaining platelet counts >20 000/μl of 12 (range 9–25) days. Isolated skin acute graft-versus-host disease (GVHD) of stages I to II occurred in three patients. One patient developed secondary graft failure and was successfully salvaged by an unmanipulated blood stem cell graft from the same donor. All 10 patients are surviving in complete hematologic, cytogenetic and molecular remission (four patients after donor lymphocyte infusions) between 12 and 22 (median 16) months post transplant. In conclusion, transplantation of MACS-purified blood CD34+ cells from HLA-identical sibling donors in adult CML patients appears safe, effectively prevents acute GVHD without prophylactic post-transplant immunosuppression, and is capable of inducing complete cytogenetic and molecular remissions. Bone Marrow Transplantation (2000) 26, 823–829.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. McNiece I, Briddell R, Stoney G et al. Large-scale isolation of CD34+ cells using the Amgen cell selection device results in high levels of purity and recovery J Hematother 1997 6: 5–11

    Article  CAS  Google Scholar 

  2. Schumm M, Lang P, Taylor G et al. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device J Hematother 1999 8: 209–218

    Article  CAS  Google Scholar 

  3. Berenson RJ, Andrews RG, Bensinger WI et al. Antigen CD34+ marrow cells engraft lethally irradiated baboons J Clin Invest 1988 81: 951–955

    Article  CAS  Google Scholar 

  4. Berenson RJ, Bensinger WI, Hill RS et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma Blood 1991 77: 1717–1722

    CAS  PubMed  Google Scholar 

  5. Corringham RE, Ho AD . Rapid and sustained allogeneic transplantation using immunoselected CD34(+)-selected peripheral blood progenitor cells mobilized by recombinant granulocyte- and granulocyte–macrophage colony-stimulating factors Blood 1995 86: 2052–2054

    CAS  PubMed  Google Scholar 

  6. Civin CI, Trischmann T, Kadan NS et al. Highly purified CD34-positive cells reconstitute hematopoiesis J Clin Oncol 1996 14: 2224–2233

    Article  CAS  Google Scholar 

  7. Link H, Arseniev L, Bähre O et al. Transplantation of allogeneic CD34+ blood cells Blood 1996 87: 4903–4909

    CAS  PubMed  Google Scholar 

  8. Finke J, Brugger W, Bertz H et al. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors Bone Marrow Transplant 1996 18: 1081–1086

    CAS  PubMed  Google Scholar 

  9. Yabe H, Yabe M, Hattori K et al. Successful engraftment of allogeneic CD34-enriched marrow cell transplantation from HLA-mismatched parental donors Bone Marrow Transplant 1996 17: 985–991

    CAS  PubMed  Google Scholar 

  10. Hale G, Zhang MJ, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection Blood 1998 92: 4581–4590

    CAS  PubMed  Google Scholar 

  11. Watts MJ, Sullivan AM, Ings SJ et al. Evaluation of clinical scale CD34+ cell purification: experience of 71 immunoaffinity column procedures Bone Marrow Transplant 1997 20: 157–162

    Article  CAS  Google Scholar 

  12. de Wynter EA, Ryder D, Lanza F et al. Multicentre European study comparing selection techniques for the isolation of CD34+ cells Bone Marrow Transplant 1999 23: 1191–1196

    Article  CAS  Google Scholar 

  13. Wiesneth M, Schreiner T, Bunjes D et al. Comparison of T-cell-depleted BMT and PBPCT with respect to chimerism, graft rejection, and leukemic relapse J Hematother 1999 8: 269–274

    Article  CAS  Google Scholar 

  14. Bahceci E, Read EJ, Leitman S et al. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies Br J Haematol 2000 108: 408–414

    Article  CAS  Google Scholar 

  15. Ottinger H, Beelen DW, Scheulen B et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow Blood 1996 88: 2775–2779

    CAS  PubMed  Google Scholar 

  16. Elmaagacli AH, Beelen DW, Opalka B et al. The risk of residual molecular and cytogenetic disease in patient with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared to bone marrow Blood 1999 94: 384–389

    CAS  PubMed  Google Scholar 

  17. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562–1568

    Article  CAS  Google Scholar 

  18. Urbano-Ispizua A, Solano C, Brunet S et al. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique Bone Marrow Transplant 1998 22: 519–525

    Article  CAS  Google Scholar 

  19. Kernan NA, Collins NH, Juliano L et al. Clonable T lymphocytes in T-cell-depleted bone marrow transplants correlate with development of graft-v-host disease Blood 1986 68: 770–773

    CAS  PubMed  Google Scholar 

  20. Briones J, Urbano-Ispizua A, Lawler M et al. High frequency of donor chimerism after allogeneic transplantation of CD34+-selected peripheral blood cells Exp Hematol 1998 26: 415–420

    CAS  PubMed  Google Scholar 

  21. Beelen DW, Ottinger HD, Elmaagacli A et al. Transplantation of Filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative donors in patients with hematologic malignancies: a prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerism Blood 1997 90: 4725–4735

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are indebted to the technicians of the blood cell separator unit and the experimental hematology and molecular biology laboratories at the Department of Bone Marrow Transplantation for their skillful expertise in performing the cell preparative work and analytical investigations. We further thank the technicians of the cytogenetic laboratory at the Department of Internal Medicine (Tumour Research) for performing the cytogenetic investigations. This work was supported in part by a grant from ‘Deutsche Krebshilfe’ (Project-No. 70–1669-EL I) and a grant from Amgen GmbH, München, Germany.

Author information

Authors and Affiliations

  1. Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany

    DW Beelen, R Peceny, A Elmaagacli, H Ottinger, G Kummer & UW Schaefer

  2. Department of Internal Medicine (Tumour Research), University Hospital of Essen, Essen, Germany

    B Opalka & S Seeber

Authors
  1. DW Beelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Peceny
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Elmaagacli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Ottinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Kummer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B Opalka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Seeber
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. UW Schaefer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beelen, D., Peceny, R., Elmaagacli, A. et al. Transplantation of highly purified HLA-identical sibling donor peripheral blood CD34+ cells without prophylactic post-transplant immunosuppression in adult patients with first chronic phase chronic myeloid leukemia: results of a phase II study. Bone Marrow Transplant 26, 823–829 (2000). https://doi.org/10.1038/sj.bmt.1702635

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702635

Keywords

This article is cited by

Search

Advanced search

Quick links